Compare VELO & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | IPSC |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.0M | 362.5M |
| IPO Year | 2020 | 2021 |
| Metric | VELO | IPSC |
|---|---|---|
| Price | $12.50 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $4.25 |
| AVG Volume (30 Days) | ★ 1.7M | 530.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.96 | ★ 91.30 |
| EPS | N/A | ★ N/A |
| Revenue | $45,973,000.00 | ★ $109,164,000.00 |
| Revenue This Year | $42.22 | N/A |
| Revenue Next Year | $50.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.12 | ★ 1556.76 |
| 52 Week Low | $2.87 | $0.44 |
| 52 Week High | $31.75 | $2.97 |
| Indicator | VELO | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 45.18 | 52.61 |
| Support Level | $12.06 | $2.10 |
| Resistance Level | $15.92 | $2.39 |
| Average True Range (ATR) | 1.33 | 0.10 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 7.43 | 84.62 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.